Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2250162 | 1.00 | CYP2D6 (0.36) | CYP2D6 | |
| Hydrochloric Acid SCHEMBL3506319 | 1.00 | CYP2D6 (0.36) | CYP2D6 | |
| SCHEMBL408683 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL6255427 | 0.74 | ALDH1A1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL4352142 | 0.74 | ALDH1A1 (0.39) | — | |
| SCHEMBL11589604 | 0.74 | — | — | |
| SCHEMBL9687721 | 0.71 | CYP2D6 (0.41) | CYP2D6 | |
| Sulfuric Acid SCHEMBL11386889 | 0.71 | CA5A (0.43) | CYP2D6 | |
| SCHEMBL24932188 | 0.67 | — | — | |
| SCHEMBL10112049 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008527-B1 | Octafluoropentaerythrityltetramine (octafluoro-peta) and process for its preparation | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2011-08-30 | — | — | US | claimed |
| EP-0680487-A1 | DISACCHARIDE LIGANDS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-11-08 | — | — | EP | claimed |
| WO-1994017084-A1 | DISACCHARIDE LIGANDS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-08-04 | — | — | WO | claimed |
| WO-2026104409-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026002831-A3 | A SCALABLE PROCESS FOR THE MANUFACTURE OF 2,2-BIS(AMINOMETHYL)PROPANE-1,3-DIAMINE TETRAHYDROCHLORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741400-A1 | MULTIMERIC MANGANESE CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260015331-A1 | Process Or The Preparation Of A Gadolinium Contrast Agent | BAYER AG (DE) | 2026-01-15 | — | — | US | disclosed |
| EP-4676535-A1 | MULTI-ALBUMIN BINDING COMPOUNDS | Ascendis Pharma A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| EP-4676537-A1 | COMPOUNDS OF DRUGS WITH AN ALBUMIN BINDING MOIETY | Ascendis Pharma A/S (DK) | 2026-01-14 | — | — | EP | disclosed |
| WO-2026002831-A2 | A SCALABLE PROCESS FOR THE MANUFACTURE OF 2,2-BIS(AMINOMETHYL)PROPANE-1,3-DIAMINE TETRAHYDROCHLORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-02 | — | — | WO | disclosed |
| WO-2026000248-A1 | A SCALABLE PROCESS FOR THE MANUFACTURE OF 2, 2-BIS (AMINOMETHYL) PROPANE-1, 3-DIAMINE TETRAHYDROCHLORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-02 | — | — | WO | disclosed |
| EP-1487851-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | Nuevolution A/S (DK) | 2004-12-22 | — | — | EP | disclosed |
| EP-1402024-A2 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | Nuevolution A/S (DK) | 2004-03-31 | — | — | EP | disclosed |
| US-20040049008-A1 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2004-03-11 | — | — | US | disclosed |
| WO-2003078627-A2 | A BUILDING BLOCK CAPABLE OF FUNCTIONAL ENTITY TRANSFER TO NUCLEOPHIL | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003078625-A2 | AN IMPROVED METHOD FOR SYNTHESISING TEMPLATED MOLECULES | NUEVOLUTION A/S (DK) | 2003-09-25 | — | — | WO | disclosed |
| WO-2002103008-A2 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2002-12-27 | — | — | WO | disclosed |
| EP-1223984-A2 | COMPOUNDS THAT ASSOCIATE ON THE INTERMOLECULAR LEVEL AND AGGREGATE BODIES THAT CONTAIN THEM | Syntesome Gesellschaft Fur Med. Biochemie M.B.H. (DE) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001002018-A2 | COMPOUNDS THAT ASSOCIATE ON THE INTERMOLECULAR LEVEL AND AGGREGATE BODIES THAT CONTAIN THEM | SYNTESOME GESELLSCHAFT FÜR MEDIZINISCHE BIOCHEMIE MBH (DE) | 2001-01-11 | — | — | WO | disclosed |
| WO-1995001966-A1 | IODINATED OLIGOMERIC COMPOUNDS AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME | BRACCO S.P.A. (IT) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049008-A1 | Templated molecules and methods for using such molecules | INTS6, ABL1, INMT | CYP2D6 568/4885 |
| US-20260015331-A1 | Process Or The Preparation Of A Gadolinium Contrast Agent | AQP3, AQP4, AQP1 | CYP2D6 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.